Element of the virus responsible for inflammation in viral keratoconjunctivitis isolated

Article

Researchers in the Howe Laboratory, Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary and Harvard Medical School, and in the University of Oklahoma Health Sciences Center, have used a novel model to determine what part of the virus is responsible for the inflammation in viral keratoconjunctivitis

Researchers in the Howe Laboratory, Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary and Harvard Medical School, and in the University of Oklahoma Health Sciences Center, have used a novel model to determine what part of the virus is responsible for the inflammation in viral keratoconjunctivitis.

Using a unique mouse model of adenovirus keratitis, Dr Chodosh and his team studied the role of viral components in the cornea to determine which viral part(s) induce an innate immune response. The authors found that neither viral DNA nor viral gene expression was necessary for inflammation. In contrast, viral capsid, the protein coat of the virus, induced inflammation similar to intact virus. Mice lacking the toll-like receptor 9 molecule, which acts as a pathogen DNA-sensing molecule within the cell, developed clinical inflammation upon adenovirus infection similar to wild type mice. Virus associated inflammation in the mouse cornea could be blocked by a treatment with a peptide containing components of the adenoviral capsid. Adenovirus infection of the cornea induces inflammation principally through contact between the viral capsid and the host cell.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.